But while the
devices might help smokers quit their habit, some researchers are
concerned that people will become addicted to the nicotine in
e-cigarettes instead. The long term health consequences are vaping are
not yet well known.
become cancerous, some proteins on their outer membranes shed sugar
molecules and become less slimy, perhaps because they're crowded closer
together. If we tune the MRI to detect sugars attached to a particular
protein, we can see the difference between normal and cancerous cells.
When are the
costs of surgery too great? It’s long been a burning question in
prostate cancer, and papers presented over the past few days at the
European Association of Urology’s conference in Madrid have added a few
more pieces to the risk versus benefits jigsaw.
markets are gearing up for the expiry of patents on some of the first
targeted cancer drugs. It's good news for greater access, but patients
want reassurance that switching to generics wont put them at risk.
after Pfizer stepped up with a $2.85 billion promise to partner with
Merck KGaA on a preclinical PD-L1 oncology effort, the German pharma
company has turned around to partner with Intrexon on an upstart CAR-T
cancer drug development project.
approaches with checkpoint inhibitors and T-cell modulation are potent
but only in select tumor types. STING agonists have the potential to
fully activate the immune system to attack a broader range of tumors.
aims to develop new immunotherapy treatments for cancer based on
preclinical work by the Southampton group showing the potential to treat
cancer using antibodies targeting OX40 and 4-1BB – known ‘co-receptors’
that help stimulate the production of killer T-cells during an immune
a monoclonal antibody that binds to a molecule known as GD2. This
molecule, a ganglioside (a complex molecule that contains both lipids
and carbohydrates), is expressed on the surface of neuroblastoma cells.
Binding of dinutuximab to GD2 initiates an immune response that can kill
finalized guidance document, Critical Path Innovation Meetings, explains
how stakeholders can set up meetings with FDA to discuss a methodology
or technology which might enhance drug development.
In a letter to
colleagues announcing his departure as the director of the National
Cancer Institute, Dr. Harold Varmus, 75, quoted Mae West. “I’ve been
rich and I’ve been poor,” he wrote, “and rich is better.”
The new report
suggests that some of the differences in rates of breast cancer
incidence and mortality across racial and ethnic groups are related to
differences in the incidence of different subtypes.
published in the Journal of the National Cancer Institute, is the latest
in a series of annual reports on cancer compiled since 1998 by the
NAACCR, the ACS, the Centers for Disease Control and Prevention and the
National Cancer Institute.
right-to-die movement has gained renewed momentum in California and
around the nation following the highly publicized death of Brittany
Maynard. The 29-year-old with brain cancer moved from California to
Oregon to take advantage of its "Death with Dignity" law and died in
November after taking a fatal dose of barbiturates prescribed by her
launches next month, Choosing Wisely Australia® will start an important
national conversation about reducing the many low value and often
potentially harmful tests, treatments and procedures that have become
entrenched in healthcare.
always be in our midst for one simple scientific reason: the very genes
that allow us to grow and adapt, when mutated, lead to cancer. And these
are not incidental genes – we are not talking about the periphery of
human physiology – we are talking about the genes that function as the
centerpieces of normal cellular growth and development.
days will illustrate what I am referring to: how we communicate about
the exciting work that is presently going on at NCI and in the cancer
research community, but also about the future of cancer research and
Unusual for a
TV story, the anecdotes presented balanced positive findings with one
cautionary tale in the form of a woman who underwent the procedure,
became partially paralyzed, dropped out of the trial and died.
More than 40
members of the AACR, including the AACR’s President-elect José Baselga,
MD, PhD, and immediate Past President Charles Sawyers, MD, are featured
in the documentary, along with 17 fellows of the AACR Academy.